Tri-Allelic Haplotypes Determine and Differentiate Functionally Normal Allele CYP2D6*2 and Impaired Allele CYP2D6*41.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
26
06
2020
accepted:
05
10
2020
pubmed:
13
10
2020
medline:
16
9
2021
entrez:
12
10
2020
Statut:
ppublish
Résumé
CYP2D6 metabolizes 20-25% of all clinically used drugs and its complex genetic polymorphism is a major determinant of drug safety and efficacy. We investigated the basis for the functional difference between the two common alleles *2 (g.2851C>T + g.4181G>C, normal function) and *41 (additional intronic g.2989G>A, reduced function). A recently reported far-distant enhancer polymorphism rs5758550A/G linked to *2 has been suggested to play a decisive role. Genotyping of two white cohorts confirmed strong linkage of rs5758550G to *2, whereas no influence was found on metabolic ratio of sparteine or hepatic expression. Genomic plasmid constructs carrying individual variants or combinations thereof were expressed in COS1 and Huh7 cells. Both g.2851C>T(R296C) and g.2989G>A reduced enzyme activity and protein levels similarly by ~ 50-65% compared to reference (*1), whereas the double variant had only ~ 20% activity. Although the unexpected loss of function caused by g.2851C>T was compensated by g.4181G>C (mimicking the EM-phenotype of *2), the additional loss of function due to intronic g.2989G>A in the triple variant was not compensated (mimicking the IM-phenotype of *41). We also confirmed increased erroneous splicing in carriers of g.2989G>A but not of g.2851C>T as a likely explanation for the impaired function of *41. In conclusion, our data demonstrate g.2989G>A as causal variant of impaired allele CYP2D6*41 whereas triple-haplotypes have to be considered to explain the functional difference between *2 and *41. These data are important for genotyping strategies and clinical implementation of CYP2D6 pharmacogenetics.
Substances chimiques
Cytochrome P-450 CYP2D6
EC 1.14.14.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1256-1264Informations de copyright
© 2020 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Meyer, U.A. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet. 5, 669-676 (2004).
Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W.E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).
Zanger, U.M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103-141 (2013).
Daly, A.K. et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6, 193-201 (1996).
Zanger, U.M., Raimundo, S. & Eichelbaum, M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369, 23-37 (2004).
Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-13 (2005).
Nofziger, C. et al. PharmVar GeneFocus: CYP2D6. Clin. Pharmacol. Ther. 107, 154-170 (2020).
Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T. & Leeder, J.S. Prediction of CYP2D6 phenotype from genotype across world populations. Genet. Med. 19, 69-76 (2017).
US Food and Drug Administration (FDA). Table of Pharmacogenomic Biomarkers in Drug Labeling: Content current as of 02/05/2020 <https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling>. Accessed June 25, 2020.
Crews, K.R. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther. 95, 376-382 (2014).
Hicks, J.K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther. 98, 127-134 (2015).
Bell, G.C. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin. Pharmacol. Ther. 102, 213-218 (2017).
Goetz, M.P. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and tamoxifen therapy. Clin. Pharmacol. Ther. 103, 770-777 (2018).
Caudle, K.E. et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch Pharmacogenetics Working Group. Clin. Transl. Sci. 13, 116-124 (2020).
Dunnenberger, H.M. et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu. Rev. Pharmacol. Toxicol. 55, 89-106 (2015).
Kalman, L.V. et al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin. Pharmacol. Ther. 99, 172-185 (2016).
van der Wouden, C.H. et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin. Pharmacol. Ther. 101, 341-358 (2017).
Cavallari, L.H. et al. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet. Med. 21, 2255-2263 (2019).
Raimundo, S. et al. A novel intronic mutation, 2988GA, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin. Pharmacol. Ther. 76, 128-138 (2004).
Abduljalil, K. et al. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin. Pharmacol. Ther. 88, 643-651 (2010).
Haslemo, T., Eliasson, E., Jukić, M.M., Ingelman-Sundberg, M. & Molden, E. Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. Br. J. Clin. Pharmacol. 85, 194-201 (2019).
Frederiksen, T., Areberg, J., Schmidt, E., Bjerregaard, S.T. & Brøsen, K. Quantification of in vivo metabolic activity of CYP2D6 genotypes and alleles through population pharmacokinetic analysis of vortioxetine. Clin. Pharmacol. Ther. 109, 150-159 (2021).
Jukic, M.M., Smith, R.L., Haslemo, T., Molden, E. & Ingelman-Sundberg, M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry 6, 418-426 (2019).
Thorén, L. et al. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. Br. J. Clin. Pharmacol. 10.1111/bcp.14500. [e-pub ahead of print].
Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E.U., Schwab, M. & Zanger, U.M. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10, 577-581 (2000).
Zanger, U.M. et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11, 573-585 (2001).
Toscano, C. et al. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988GA: evidence for modulation of splicing events. Pharmacogenet. Genomics 16, 755-766 (2006).
Wang, D., Poi, M.J., Sun, X., Gaedigk, A., Leeder, J.S. & Sadee, W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum. Mol. Genet. 23, 268-278 (2014).
Wang, D., Papp, A.C. & Sun, X. Functional characterization of CYP2D6 enhancer polymorphisms. Hum. Mol. Genet. 24, 1556-1562 (2015).
Ray, B., Ozcagli, E., Sadee, W. & Wang, D. CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): Implications for CYP2D6 genotyping panels. Pharmacogenet. Genomics 29, 39-47 (2019).
Boone, E.C. et al. Long-distance phasing of a tentative "enhancer" single-nucleotide polymorphism with CYP2D6 star allele definitions. Front. Pharmacol. 11, 486 (2020).
Klein, K. et al. A new panel-based next-generation sequencing method for ADME genes reveals novel associations of common and rare variants with expression in a human liver cohort. Front. Genet. 10, 7 (2019).
Feidt, D.M. et al. Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metab. Dispos. 38, 1589-1597 (2010).
Auton, A. et al. A global reference for human genetic variation. Nature 526, 68-74 (2015).
Karczewski, K.J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434-443 (2020).
Sanchez-Spitman, A.B., Moes, D.-J.-A., Gelderblom, H., Dezentjé, V.O., Swen, J.J. & Guchelaar, H.-J. The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen. Pharmacogenomics 18, 1125-1132 (2017).
Ning, M., Duarte, J.D., Rubin, L.H. & Jeong, H. CYP2D6 protein level is the major contributor to interindividual variability in CYP2D6-mediated drug metabolism in healthy human liver tissue. Clin. Pharmacol. Ther. 104, 974-982 (2018).
Marcucci, K.A., Pearce, R.E., Crespi, C., Steimel, D.T., Leeder, J.S. & Gaedigk, A. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab. Dispos. 30, 595-601 (2002).
Sakuyama, K. et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab. Dispos. 36, 2460-2467 (2008).
Niwa, T., Murayama, N. & Yamazaki, H. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition. Curr. Drug Metab. 12, 412-435 (2011).
Dong, A.N., Ahemad, N., Pan, Y., Palanisamy, U.D., Yiap, B.C. & Ong, C.E. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition. Naunyn Schmiedebergs Arch. Pharmacol. 392, 1015-1029 (2019).
Dong, C. et al. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum. Mol. Genet. 24, 2125-2137 (2015).
Zhou, Y., Mkrtchian, S., Kumondai, M., Hiratsuka, M. & Lauschke, V.M. An optimized prediction framework to assess the functional impact of pharmacogenetic variants. Pharmacogenomics J. 19, 115-126 (2019).
Marez, D. et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7, 193-202 (1997).
Elias, A.B.R., Araújo, G.S.D., Souza, S.J. & Suarez-Kurtz, G. Distribution and linkage disequilibrium of the enhancer SNP rs5758550 among Latin American populations: influence of continental ancestry. Pharmacogenet. Genomics 30, 67-72 (2020).